All sponsors

Vanda Pharmaceuticals $VNDA

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-310
RECRUITING9
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO33%

Delay Index: of 9 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Vanda Pharmaceuticals on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tradipitant
NCT04326426
P3Enrolling by invitationCoronavirus Infection3002020-08-01
Tasimelteon
NCT06701396
P3RecruitingSleep Wake Disorders; Sleep Disorders, Circadian Rhythm602025-06-30
Trichostatin A
NCT07065773
P2Active, not recruitingOnychomycosis of Toenail502026-09 (+6 mo)
VSJ-110
NCT07179055
P2RecruitingDry Eye1602026-09
iloperidone
NCT07090161
P2RecruitingHypertension; Uncontrolled Hypertension2402026-10
VQW-765
NCT07221578
P3Active, not recruitingSocial Anxiety Disorder (SAD)5002026-12
Tradipitant
NCT07446439
P3RecruitingNausea and Vomiting; Obesity2802026-12-01
VCA-894A
NCT07223632
P1/2Active, not recruitingCharcot Marie Tooth Disease (CMT); Neuromuscular Diseases (NMD)12027-03 (+12 mo)
Tradipitant
NCT06138613
P3Active, not recruitingMotion Sickness7052027-09-30 (+38 mo)
iloperidone
NCT06961968
P3RecruitingSchizophrenia4002027-11
Tasimelteon Oral Suspension
NCT06953869
P3RecruitingInsomnia Disorder4202027-11
Milsaperidone
NCT06830044
P3RecruitingMajor Depressive Disorder (MDD)5002028-03
Ponesimod
NCT07362017
P3RecruitingModerate-to-severe Chronic Plaque Psoriasis3002028-08
Ponesimod
NCT07686081
P3RecruitingUlcerative Colitis (UC)1502029-04